

June 15, 2025

To,

**Department of Corporate Relationship  
BSE Ltd.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001.  
Scrip Code: 539177

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051  
NSE Symbol – AIIL

Dear Sir / Madam,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)**

In continuation to our disclosure dated June 13, 2025, we wish to inform that the Company had, on June 13, 2025, entered into a Commercial Transaction (“**Agreement**”) with *inter alia* Devicam Capital LLP, a limited liability partnership, existing under the laws of India, having LLP Identification Number (LLPIN: AAB-9882) and having its registered office at Cepha Block, First Floor, Sy No 152/6 and 154/16 Dorasani Palya, Begur Hobli, Bannerghatta Road, Bangalore, Karnataka, India, 560076 (“**Devicam**”) and Pronomz Ventures LLP, a limited liability partnership, existing under the laws of India, having LLP Identification Number (LLPIN: AAA-3757) and having its registered office at Cepha Block, First Floor, Sy No 152/6 and 154/16, Dorasani Palya, Begur, Hobli, Bannerghatta Road, Bangalore, Bangalore South, Karnataka, India, 560076 (“**Pronomz**”), to record *inter alia* the terms of the Agreement, by way of transfer of ownership in 39,27,000 (Thirty Nine Lakh Twenty Seven Thousand) shares of OneSource Specialty Pharma Limited (NSE: ONESOURCE | BSE: 544292), a public limited company, existing under the laws of India, having corporate identification number (CIN): L74140MH2007PLC432497 and having its registered office at Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, India, 400703 (“**OneSource Specialty**”) to the Company.

Pursuant to the transactions contemplated under the Agreement, the Company acquired 3.43% (three point four three per cent) of the voting rights in OneSource Specialty, as calculated on a fully diluted basis.

Further, the details required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure A**.

Kindly take the same on your records.

Thanking you,

For **Authum Investment & Infrastructure Limited**

**Amit Dangi**  
**Whole Time Director**  
**DIN: 06527044**

**Annexure A**

Disclosure of information pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Name of the target entity, details in brief such as size, turnover etc.;	<p>OneSource Specialty Pharma Limited (NSE: ONESOURCE   BSE: 544292), a public limited company, existing under the laws of India, having corporate identification number (CIN): L74140MH2007PLC432497 and having its registered office at Unit No. 902, Cyber One, Plot No - 4 &amp; 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, India, 400703 (<b>“OneSource Specialty”</b>)</p> <p>Net Worth of OneSource Specialty (as of March 31, 2025): 5,880 Crores</p> <p>Turnover of OneSource Specialty (as of March 31, 2025): 1444.8Crores</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired. If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No
Industry to which the entity being acquired belongs;	Pharmaceuticals.
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company acquired the shares of OneSource Specialty, as part of a Commercial Transaction.
Brief details of any governmental or regulatory approvals required for the acquisition;	No governmental or regulatory approvals are envisaged to be required.
Indicative time period for completion of the acquisition;	June 13, 2025
Consideration - whether cash consideration or share swap or any other form and details of the same;	<p>Acquisition of 39,27,000 (Thirty-Nine Lakh Twenty Seven Thousand) shares of OneSource Specialty Pharma Limited (NSE: ONESOURCE   BSE: 544292) is in consideration of a Commercial Transaction.</p> <p>The fair market value of such shares, as on June 13 2025, as per the price on National Stock Exchange</p>

**Registered Office :** 707, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai - 400 021.

**Ph.:** (022) 6747 2117 ♦ **E-mail:** info@authum.com ♦ **Website :** www.authum.com

**Corporate Office:** The Ruby, 11<sup>th</sup> Floor, North- West Wing, Plot No. 29, Senapati Bapat Marg, Dadar (West), Mumbai – 400 028.

**T +91 22 6838 8100 ♦ Customer Service: T +91 22 4741 5800 ♦ E-mail:** customercare@authum.com

	of India is INR 2,028 per share aggregating to INR 796,39,56,000/- (Indian Rupees Seven Hundred Ninety-Six Crores Thirty-Nine Lakhs Fifty Six Thousand only).
Cost of acquisition and/or the price at which the shares are acquired;	<p>Acquisition of 39,27,000 (Thirty-Nine Lakh Twenty-Seven Thousand) shares of OneSource Specialty Pharma Limited (NSE: ONESOURCE   BSE: 544292) is in consideration of a Commercial Transaction.</p> <p>The fair market value of such shares, as on June 13 2025, as per the price on National Stock Exchange of India is INR 2,028 per share aggregating to INR 7,96,39,56,000/- (Indian Rupees Seven Hundred Ninety-Six Crores Thirty-Nine Lakhs Fifty Six Thousand only).</p>
Percentage of shareholding / control acquired and / or number of shares acquired;	Pursuant to the transactions contemplated under the Agreement, the Company acquired 3.43% (three point four three per cent) of the voting rights in OneSource Specialty.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p><b>Brief Background of OneSource</b> OneSource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, is India's first specialty pharma pure-play Contract Development and Manufacturing Organization (CDMO). Established in 2007 and headquartered in Bengaluru, the company was rebranded in February 2024 following a strategic restructuring process.</p> <p><b>Line of Business</b> Pharmaceuticals</p> <p><b>Date of Incorporation:</b> June 12, 2007</p> <p><b>Turnover of last 3 years</b> FY 22-23: Rs. 41.07 Crores; FY 23-24: Rs. 171.90 Crores, FY 24-25: Rs. 1,444.8 Crores</p> <p><b>Country in which the acquired entity has presence:</b> India</p>

**Registered Office :** 707, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai - 400 021.

**Ph.:** (022) 6747 2117 ♦ **E-mail:** info@authum.com ♦ **Website :** www.authum.com

**Corporate Office:** The Ruby, 11<sup>th</sup> Floor, North- West Wing, Plot No. 29, Senapati Bapat Marg, Dadar (West), Mumbai – 400 028.

**T** +91 22 6838 8100 ♦ **Customer Service:** T +91 22 4741 5800 ♦ **E-mail:** customercare@authum.com